Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients
NCT04943224
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
12
Enrollment
OTHER
Sponsor class
Conditions
Histiocytosis
Interventions
DRUG:
Trametinib
Sponsor
Anna Raciborska
Collaborators
[object Object]
[object Object]
[object Object]